ERBB2 and breast cancer: Based on current knowledge, taxanes should be considered as therapy backbone in standard cytotoxic treatment of early breast cancer and thus, further analyses evaluating the impact of anthracyclines for adjuvant chemotherapy in high-risk HER2-negative early breast cancer patients have to come from taxane-treated patient cohorts.